Intellectual Property Licensing
•126 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (126)
%
| Company | Market Cap | Price |
|---|---|---|
|
The company holds exclusive worldwide licenses for drug programs, reflecting Intellectual Property Licensing activity.
|
$13.56M |
$1.44
-4.64%
|
|
TXMD's direct business is licensing its pharmaceutical IP and collecting royalties from partners for IMVEXXY, BIJUVA, and ANNOVERA.
|
$12.41M |
$1.07
+1.16%
|
|
Licensing of intellectual property, including ToolKITT software and autonomous manipulators, supports royalties/revenue streams.
|
$12.23M |
$2.95
-11.68%
|
|
Licensing of novel iPSC-based cardiac cells indicates Intellectual Property Licensing activity.
|
$12.20M |
$0.81
-7.66%
|
|
Plan to monetize legacy biotech IP via licensing, representing an intellectual property licensing activity.
|
$11.28M |
$1.98
-10.41%
|
|
Emerson licenses intellectual property/assets (trademarks/IP) in addition to its brand, a distinct IP licensing stream.
|
$10.89M |
$0.52
-14.69%
|
|
Intellectual Property Licensing: Strategy to own and license technology for monetization and partnerships.
|
$10.85M |
$1.06
-7.83%
|
|
Gelteq's core business is out-licensing its patent-pending gel delivery technology, making Intellectual Property Licensing central to its strategy.
|
$10.55M |
$1.30
-2.99%
|
|
The company monetizes its underlying technology through an Intellectual Property Licensing agreement with a related-party, representing an IP licensing business model.
|
$10.44M |
$2.13
-9.36%
|
|
Intellectual Property Licensing – SleepX IP licensing.
|
$10.37M |
$0.02
-13.97%
|
|
ParkerVision's core business is the licensing and enforcement of its RF patents, i.e., intellectual property licensing as the primary revenue model.
|
$8.94M |
$0.37
-2.63%
|
|
Business model centers on licensing intellectual properties to partners; primary IP licensing activity.
|
$7.69M |
$0.64
+0.47%
|
|
Licensing IP and MEA manufacturing know-how is a central business model and revenue stream.
|
$7.66M |
$2.87
-7.42%
|
|
Company engages in Intellectual Property Licensing (licensing hCDR1 to partners like Yeda).
|
$7.63M |
$1.40
-11.39%
|
|
Company monetizes assets through licensing and IP licensing agreements (e.g., Praliciguat, Zagociguat), indicating direct IP licensing activity.
|
$7.48M |
$2.33
-5.67%
|
|
Company licenses technology from institutions, indicating IP licensing activity as a core business element.
|
$6.92M |
$1.56
-0.95%
|
|
The company is pursuing licensing/joint venture models for its AquaRefining tech, i.e., Intellectual Property Licensing.
|
$6.49M |
$7.79
+6.78%
|
|
Company holds an exclusive worldwide license for BET inhibitor technology, aligning with Intellectual Property Licensing.
|
$5.53M |
$0.33
+5.00%
|
|
Maxeon monetizes its extensive IP portfolio through Intellectual Property Licensing and related licensing activities.
|
$5.11M |
$3.36
-7.44%
|
|
QTY code protein design intellectual property may be monetized via licensing.
|
$4.24M |
$2.27
+1.12%
|
|
Licensing of intellectual property and platform assets represents a core IP licensing business model.
|
$2.93M |
$0.35
-11.14%
|
|
Piclidenoson and Namodenoson are out-licensed and licensed IP assets, fitting Intellectual Property Licensing.
|
$2.66M |
$0.53
-7.02%
|
|
Involves licensing and commercialization of intellectual property (IP) across media projects.
|
$1.92M |
$0.79
-3.90%
|
|
Intellectual property licensing related to NSAT technologies.
|
$1.73M |
$0.06
|
|
Out-licensing of the EVM201 series and ongoing IP monetization indicate an IP Licensing business line.
|
$1.71M |
$0.68
-1.76%
|
|
Revenue model includes licensing IP/licensing arrangements with related parties and third parties.
|
$703985 |
$0.02
-41.18%
|
Showing page 2 of 2 (126 total stocks)
Loading industry metrics...
Loading comparison data...
